Search
epinephrine inhaler (Asthmanefrin, Primatene Mist)
Asthmanefrin is racemic epinephrine
Indications:
- mild, intermittent asthma (OTC)
Dosage:
- 0.5 mL vial contains 11.25 mg racepinephrine (1% epinephrine)
- for use with a battery-operated atomizer that creates a mist that is inhaled into the lungs via a mouthpiece or mask [3]
Notes:
- Primatene mist removed from market in 2011 due to use of chlorofluorocarbon (CFC) propellants.
- new version* of over-the-counter Primatene Mist FDA-approved Nov 2018 [4]
* metered-dose inhaler works in a different way than its 2011 predecessor [4]
Interactions
drug adverse effects of adrenergic receptor agonists
General
epinephrine; adrenaline (Sus-Phrine, Vapronefrin, Epifrin, Glaucon, Auvi-Q, Allerject)
pulmonary agent
References
- Prescriber's Letter 13(3): 2006
Status of OTC Epinephrine Inhalers
Detail-Document#: 220311
(subscription needed) http://www.prescribersletter.com
- Physician's First Watch, Aug 27 2012
Massachusetts Medical Society
http://www.jwatch.org
- NEPHRON ANNOUNCES ASTHMANEFRINTM, AN ALTERNATIVE TO
PRIMATENE MIST
http://www.nephronpharm.com/images/upload_images/file/FL%20Final%20Press%20Release%208-20.pdf
- Prescriber's Letter 19(10): 2012
Asthmanefrin Inhalation Solution
Detail-Document#: 281009
(subscription needed) http://www.prescribersletter.com
- FDA Statement. Nv 8, 2018
Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet
Woodcock, M.D., director of the Center for Drug Evaluation and
Research, on approval of OTC Primatene Mist to treat mild asthma.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm625338.htm